European Journal of Cancer最新文献

{"title":"The 2024 State of Science report from the European Organisation for Research and Treatment of Cancer’s Radiation Oncology Scientific Council","authors":"Daniel Portik ,&nbsp;Denis Lacombe ,&nbsp;Corinne Faivre-Finn ,&nbsp;Vérane Achard ,&nbsp;Nicolaus Andratschke ,&nbsp;Dora Correia ,&nbsp;Mateusz Spalek ,&nbsp;Matthias Guckenberger ,&nbsp;Piet Ost ,&nbsp;Felix Ehret","doi":"10.1016/j.ejca.2025.115334","DOIUrl":"10.1016/j.ejca.2025.115334","url":null,"abstract":"<div><h3>Background</h3><div>Radiotherapy (RT) is a central pillar of a multimodal cancer treatment approach. The ongoing advances in the fields of RT, imaging technologies, cancer biology, and others yield the potential to refine the use of RT. The European Organisation for Research and Treatment of Cancer (EORTC) hosted a dedicated workshop to identify and prioritize key research questions and to define future RT-based treatment strategies to improve the survival and quality of life of cancer patients.</div></div><div><h3>Methods</h3><div>An initial call for relevant RT research topics led to the formation of workgroups to develop these into new clinical research proposals and projects. The EORTC Radiation Oncology Scientific Council (ROSC) State of Science workshop was held in Brussels, Belgium, in February 2024, bringing together EORTC members and international stakeholders to connect and work on the proposals.</div></div><div><h3>Results</h3><div>Four topics of interest were identified: I) De-escalation of RT, minimizing toxicity while maintaining patients’ quality of life, II) Technology-driven RT utilizing advances in treatment techniques, such as spatially fractionated RT to improve outcomes in patients with bulky disease and localized high tumor burden, III) Biology-driven RT, integrating the rapid advances in cancer biology and functional imaging to guide and personalize RT, and IV) New indications adding value and expanding the use of RT.</div></div><div><h3>Conclusion</h3><div>The EORTC ROSC State of Science workshop prioritized clinical questions to be addressed in prospective clinical research projects to advance RT care and improve patient outcomes.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115334"},"PeriodicalIF":7.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Cancer-specific utility instrument for health economic evaluations: A synopsis of the EORTC QLU-C10D user manual and current validity evidence” [Eur J Cancer (2025) 115235]","authors":"Simone Seyringer ,&nbsp;Micha Pilz ,&nbsp;Femke Jansen ,&nbsp;Matthias Büttner ,&nbsp;Madeleine T. King ,&nbsp;Richard Norman ,&nbsp;Georg Kemmler ,&nbsp;Virginie Nerich ,&nbsp;Bernhard Holzner ,&nbsp;Andrew Bottomley ,&nbsp;Eva M. Gamper","doi":"10.1016/j.ejca.2025.115330","DOIUrl":"10.1016/j.ejca.2025.115330","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"219 ","pages":"Article 115330"},"PeriodicalIF":7.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals","authors":"Jens Lehmann ,&nbsp;Tatiana Dragan ,&nbsp;Elke Rammant ,&nbsp;Kelly M. de Ligt ,&nbsp;Julia Lai-Kwon ,&nbsp;Emma Lidington ,&nbsp;Renée Bultijnck ,&nbsp;Daniel Dejaco ,&nbsp;Katherine J. Taylor ,&nbsp;Tihana Gašpert ,&nbsp;Elena Colombo ,&nbsp;Ainhoa Madariaga ,&nbsp;Mariana Brandão ,&nbsp;Jan P. Nicolay ,&nbsp;Ioannis Zerdes ,&nbsp;Francesca Bosisio ,&nbsp;Dora Correia ,&nbsp;Alessia Pellerino ,&nbsp;Gloria Marquina ,&nbsp;Mário Fontes-Sousa ,&nbsp;Petr Szturz","doi":"10.1016/j.ejca.2025.115333","DOIUrl":"10.1016/j.ejca.2025.115333","url":null,"abstract":"<div><h3>Background</h3><div>Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional survey (November 2023-April 2024) among healthcare professionals (HCPs) in the European Organisation for Research and Treatment of Cancer (EORTC). Descriptive statistics and chi-square tests assessed PROM use patterns, regional differences, and barriers. Binary regression models compared barriers between PROM users and non-users.</div></div><div><h3>Results</h3><div>Of the 3733 EORTC members contacted, 784 responded (21 % response rate), predominantly physicians. Among the 784 HCPs (50 % women), 338 (43 %) did not use PROMs, 214 (27 %) were occasional users, and 232 (30 %) used PROMs regularly. PROM use was significantly higher in Western Europe than in Central/Eastern Europe. PROMs were primarily used for monitoring health status and enhancing communication. PROM use was highest among HCPs treating bone, soft tissue, genito-urinary, and gynecological cancers, and lowest in lung cancer. Key barriers to PROM use included lack of time (reported by 70 % of respondents) and insufficient support on how to use PROMs (73 %). Compared to non-users, PROM users more frequently identified patient-level barriers, such as accessibility concerns, as relevant (Odds Ratio 3.5, 95 % Confidence Interval 2.4–5.3).</div></div><div><h3>Conclusions</h3><div>PROM use varies by cancer type, setting, and region. Addressing time constraints, providing support, and overcoming patient barriers are key to broader integration. Ensuring equitable access to PROM tools across regions and settings is vital for promoting equity in cancer care.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115333"},"PeriodicalIF":7.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunometabolism of tumor-associated macrophages: A therapeutic perspective","authors":"Adelya F. Karimova ,&nbsp;Adelya R. Khalitova ,&nbsp;Roman Suezov ,&nbsp;Nikita Markov ,&nbsp;Yana Mukhamedshina ,&nbsp;Albert A. Rizvanov ,&nbsp;Magdalena Huber ,&nbsp;Hans-Uwe Simon ,&nbsp;Anna Brichkina","doi":"10.1016/j.ejca.2025.115332","DOIUrl":"10.1016/j.ejca.2025.115332","url":null,"abstract":"<div><div>Tumor-associated macrophages (TAMs) play a pivotal role in the tumor microenvironment (TME), actively contributing to the formation of an immunosuppressive niche that fosters tumor progression. Consequently, there has been a growing interest in targeting TAMs as a promising avenue for cancer therapy. Recent advances in the field of immunometabolism have shed light on the influence of metabolic adaptations on macrophage physiology in the context of cancer. Here, we discuss the key metabolic pathways that shape the phenotypic diversity of macrophages. We place special emphasis on how metabolic reprogramming impacts the activation status of TAMs and their functions within the TME. Additionally, we explore alterations in TAM metabolism and their effects on phagocytosis, production of cytokines/chemokines and interaction with cytotoxic T and NK immune cells. Moreover, we examine the application of nanomedical approaches to target TAMs and assess the clinical significance of modulating the metabolism of TAMs as a strategy to develop new anti-cancer therapies. Taken together, in this comprehensive review article focusing on TAMs, we provide invaluable insights for the development of effective immunotherapeutic strategies and the enhancement of clinical outcomes for cancer patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115332"},"PeriodicalIF":7.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology","authors":"Damian T. Rieke ,&nbsp;Michael Bitzer ,&nbsp;Annalen Bleckmann ,&nbsp;Alexander Desuki ,&nbsp;Thomas Ernst ,&nbsp;Irene Esposito ,&nbsp;Armin Gerger ,&nbsp;Hanno Glimm ,&nbsp;Peter Horak ,&nbsp;Daniel Hübschmann ,&nbsp;Anna Lena Illert ,&nbsp;Volker Kunzmann ,&nbsp;Sonja Loges ,&nbsp;Ina Pretzell ,&nbsp;Katja Schmitz ,&nbsp;Andreas Seeber ,&nbsp;Bärbel Söhlke ,&nbsp;Andreas Wicki ,&nbsp;Jürgen Wolf ,&nbsp;Georg Maschmeyer","doi":"10.1016/j.ejca.2025.115331","DOIUrl":"10.1016/j.ejca.2025.115331","url":null,"abstract":"<div><div>Precision oncology is a multi-step process including patient selection, tumor profiling, molecular tumor board discussion and personalized cancer management. So far, it remains largely unstandardized. The implementation of precision oncology can be beneficial for patients but implementation differs widely between tumor types and local practices. A working group was established by the Austrian, German and Swiss societies for Hematology and Medical Oncology to establish an expert consensus on evidence-based standards and implementation of precision oncology. Herein, we present a summary of this guideline. The full documents are available at www.onkopedia-guidelines.info</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115331"},"PeriodicalIF":7.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis","authors":"Guillermo Villacampa ,&nbsp;Gemma Eminowicz ,&nbsp;Victor Navarro ,&nbsp;Lorenzo Carità ,&nbsp;David García-Illescas ,&nbsp;Ana Oaknin ,&nbsp;J. Alejandro Pérez-Fidalgo","doi":"10.1016/j.ejca.2025.115329","DOIUrl":"10.1016/j.ejca.2025.115329","url":null,"abstract":"<div><h3>Background</h3><div>Several first-line therapeutic strategies have been evaluated alongside platinum-based chemotherapy in advanced or recurrent endometrial cancer (a/rEC). However, the optimal approach remains unclear.</div></div><div><h3>Methods</h3><div>A systematic review was conducted to identify randomized control trials (RCTs) that evaluate first-line therapeutic strategies in a/rEC involving immune checkpoint inhibitors (ICI) and PARP inhibitors (PARPi). A network meta-analysis with a frequentist framework using random-effects and an extracted individual patient data meta-analysis were performed. The primary endpoint was progression-free survival (PFS) by MMR status, p53 status within the MMRp population and PD-L1 status.</div></div><div><h3>Results</h3><div>A total of 3210 patients with EC were included. In the MMRp population, the combination (ICI and PARPi) showed a not statistically significant PFS benefit compared with each agent alone. In MMRp p53-abnormal patients (n = 590), combining PARPi and ICI statistically improved PFS compared to ICI alone (HR=0.47, 95 %CI 0.40–0.94) with a numerically better outcome compared to PARPi alone (HR=0.63, 95 %CI 0.26–1.57). No benefit from PARPi was observed in the p53 wild-type MMRp population. PD-L1-positivity (n = 1121) appears to predict more benefit from the addition of ICI and PARPi, with a larger benefit of combination therapy. In the MMRd population (n = 769), the best outcomes were observed with ICI alone, with no additional benefit of PARPi. Grade 3 or greater treatment-related adverse events were seen in 75.1 % patients treated with the combination.</div></div><div><h3>Conclusions</h3><div>The addition of the combination of ICI and PARPi to platinum-based chemotherapy provides greatest benefit to p53-abnormal MMRp patients. PD-L1 is a potentially useful biomarker with PD-L1-positive tumors more likely to respond to ICI. Implementation of biomarkers is crucial to redefine the treatment paradigm in a/rEC.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115329"},"PeriodicalIF":7.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction","authors":"Harriet L. Lancaster ,&nbsp;Beibei Jiang ,&nbsp;Michael P.A. Davies ,&nbsp;Jan Willem C. Gratama ,&nbsp;Mario Silva ,&nbsp;Jaeyoun Yi ,&nbsp;Marjolein A. Heuvelmans ,&nbsp;Geertruida H. de Bock ,&nbsp;Anand Devaraj ,&nbsp;John K. Field ,&nbsp;Matthijs Oudkerk","doi":"10.1016/j.ejca.2025.115324","DOIUrl":"10.1016/j.ejca.2025.115324","url":null,"abstract":"<div><h3>Purpose</h3><div>Artificial intelligence (AI) could reduce lung cancer screening computer tomography (CT)-reading workload if used as a first-reader, ruling-out negative CT-scans at baseline. Evidence is lacking to support AI performance when compared to gold-standard lung cancer outcomes. This study validated the performance of a commercially available AI software in the UK lung cancer screening (UKLS) trial dataset, with comparison to human reads and histological lung cancer outcomes, and estimated CT-reading workload reduction.</div></div><div><h3>Methods</h3><div>1252 UKLS-baseline-CT-scans were evaluated independently by AI and human readers. AI performance was evaluated on two-levels. Firstly, AI classification and individual reads were compared to a EU reference standard (based on NELSON2.0-European Position Statement) determined by a European expert panel blinded from individual results. A positive misclassification was defined as a nodule positive read ≥ 100mm³ and no/&lt;100mm³ nodules in the expert read; A negative misclassification was defined as a nodule negative read, whereas an indeterminate or positive finding in the expert read. Secondly, AI nodule classification was compared to gold-standard histological lung cancer outcomes. CT-reading workload reduction was calculated from AI negative CT-scans when AI was used as first-reader.</div></div><div><h3>Results</h3><div>Expert panel reference standard reported 815 (65 %) negative and 437 (35 %) indeterminate/positive CT-scans in the dataset of 1252 UKLS-participants. Compared to the reference standard, AI resulted in less misclassification than human reads, NPV 92·0 %(90·2 %-95·3 %). On comparison to gold-standard, AI detected all 31 baseline-round lung cancers, but classified one as negative due to the 100mm³ threshold, NPV 99·8 %(99·0 %-99·9 %). Estimated maximum CT-reading workload reduction was 79 %.</div></div><div><h3>Conclusion</h3><div>Implementing AI as first-reader to rule-out negative CT-scans, shows considerable potential to reduce CT-reading workload and does not lead to missed lung cancers.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115324"},"PeriodicalIF":7.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer","authors":"Harriet L. Lancaster ,&nbsp;Anna N.H. Walstra ,&nbsp;Kyle Myers ,&nbsp;Ricardo S. Avila ,&nbsp;Jan Willem C. Gratama ,&nbsp;Marjolein A. Heuvelmans ,&nbsp;Sean B. Fain ,&nbsp;David A. Clunie ,&nbsp;Ella A. Kazerooni ,&nbsp;Maryellen L. Giger ,&nbsp;Anthony P. Reeves ,&nbsp;Jens Vogel-Claussen ,&nbsp;Harry de Koning ,&nbsp;Rowena Yip ,&nbsp;Luis M. Seijo ,&nbsp;John K. Field ,&nbsp;James L. Mulshine ,&nbsp;Mario Silva ,&nbsp;David F. Yankelevitz ,&nbsp;Claudia I. Henschke ,&nbsp;Matthijs Oudkerk","doi":"10.1016/j.ejca.2025.115323","DOIUrl":"10.1016/j.ejca.2025.115323","url":null,"abstract":"<div><div>Reduction in lung cancer mortality is achievable through low dose computed tomography (LDCT) screening in high-risk individuals. Many countries are progressing from local LDCT screening studies to national screening programs. Implementation of effective large-scale screening programs is complex and requires a multi-disciplinary approach. A recent overview of the technical aspects of implementing high quality LDCT for screening resulted from the inaugural international expert meeting of the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE). This covers the most important aspects of the CT imaging process: standardisation in CT image acquisition and interpretation, CT protocol management, technology developments and minimal requirements, integration of lung cancer biomarkers, and the role of AI in CT lung nodule detection, segmentation, and classification, and related data security issues.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115323"},"PeriodicalIF":7.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143520170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions","authors":"Ami V. Desai ,&nbsp;Aditi Bagchi ,&nbsp;Amy E. Armstrong ,&nbsp;Cornelis M. van Tilburg ,&nbsp;Ellen M. Basu ,&nbsp;Giles W. Robinson ,&nbsp;Huanmin Wang ,&nbsp;Michela Casanova ,&nbsp;Nicolas André ,&nbsp;Quentin Campbell-Hewson ,&nbsp;Yeming Wu ,&nbsp;Alison Cardenas ,&nbsp;Bo Ci ,&nbsp;Carolina Ryklansky ,&nbsp;Clare E. Devlin ,&nbsp;Georgina Meneses-Lorente ,&nbsp;Jade Wulff ,&nbsp;Katherine E. Hutchinson ,&nbsp;Amar Gajjar ,&nbsp;Elizabeth Fox","doi":"10.1016/j.ejca.2025.115308","DOIUrl":"10.1016/j.ejca.2025.115308","url":null,"abstract":"<div><h3>Background</h3><div>Entrectinib, a central nervous system (CNS)-penetrant TRK/ROS1 inhibitor, has demonstrated clinical activity in children with <em>NTRK1/2/3</em> or <em>ROS1</em> fusion-positive extracranial solid and CNS tumours. We present integrated data of entrectinib in children with <em>NTRK</em> or <em>ROS1</em> fusion-positive tumours from the STARTRK-NG, TAPISTRY, and STARTRK-2 trials.</div></div><div><h3>Methods</h3><div>Efficacy analyses were undertaken on TRK/ROS1 inhibitor-naïve patients aged &lt;18 years with metastatic/locally advanced <em>NTRK1/2/3</em> or <em>ROS1</em> fusion-positive extracranial solid or CNS tumours who received ≥1 entrectinib dose and had ≥6 months of follow-up from enrolment. Tumour responses were confirmed by blinded independent central review (BICR) per RECIST v1.1/RANO criteria. Primary endpoint: BICR-assessed confirmed objective response rate (cORR). Key secondary endpoints: duration of response (DoR); time to response (TtR); safety.</div></div><div><h3>Results</h3><div>As of 16 July 2023, out of 91 safety-evaluable patients, 64 (<em>NTRK</em>: n=44; <em>ROS1</em>: n=20) were efficacy evaluable. In the <em>NTRK</em> and <em>ROS1</em> subgroups, respectively, median age was 4.0 years and 7.5 years; median survival follow-up was 24.2 months and 27.6 months. cORR was 72.7 % (<em>NTRK,</em> 95 % confidence interval [CI]: 57.2–85.0) and 65.0 % (<em>ROS1</em>, 95 % CI: 40.8–84.6). Median DoR was not reached (<em>NTRK,</em> 95 % CI: 25.4–not evaluable [NE]); <em>ROS1</em>, 95 % CI: 16.2–NE); median TtR was 1.9 months in both subgroups. The most frequently reported treatment-related adverse events included weight gain (35.2 %) and anaemia (31.9 %).</div></div><div><h3>Conclusion</h3><div>Integrated data from three trials confirm entrectinib induces rapid and durable responses in children with <em>NTRK</em> or <em>ROS1</em> fusion-positive tumours. The increased duration of safety monitoring does not demonstrate new or cumulative toxicity.</div><div><strong>Registered clinical trials:</strong> STARTRK-NG: NCT02650401; TAPISTRY: NCT04589845; STARTRK-2: NCT02568267</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115308"},"PeriodicalIF":7.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study","authors":"Hiroo Ishida ,&nbsp;Yu Sunakawa ,&nbsp;Yasuhiro Kodera ,&nbsp;Kazuhiro Yoshida ,&nbsp;Mitsugu Kochi ,&nbsp;Yoshihiro Kakeji ,&nbsp;Takeshi Sano ,&nbsp;Masahiro Takeuchi ,&nbsp;Wataru Ichikawa ,&nbsp;Masashi Fujii","doi":"10.1016/j.ejca.2025.115322","DOIUrl":"10.1016/j.ejca.2025.115322","url":null,"abstract":"<div><h3>Background</h3><div>As adjuvant chemotherapy for stage III gastric cancer, the phase III (JACCRO GC-07) trial showed that docetaxel plus S-1 (DS) was superior to S-1 in terms of recurrence-free and overall survival. However, whether adding docetaxel to S-1 in the adjuvant setting affects survival after recurrence remains unclear. The optimal treatment strategy for patients who develop recurrence during or after DS has also been controversial.</div></div><div><h3>Methods</h3><div>We used results from JACCRO GC-07 to investigate post-recurrence survival (PRS) in patients who developed recurrence during or after completing adjuvant chemotherapy. PRS was compared between adjuvant groups and among post-recurrence chemotherapeutic regimens.</div></div><div><h3>Results</h3><div>During 5 years of follow-up after surgery, 161 of 441 patients in the DS group and 216 of 452 patients in the S-1 group developed recurrence, with median PRS of 12.6 and 11.4 months, respectively (hazard ratio [HR] 0.98, 95 % confidence interval [CI] 0.79–1.22; p = 0.84). Among patients with recurrence, 115 patients in the DS group and 165 patients in the S-1 group received chemotherapy, and median PRS was 14.5 and 13.7 months, respectively (HR 1.04, 95 %CI 0.81–1.34; p = 0.76). Platinum-based chemotherapy resulted in longer PRS than non-platinum chemotherapy, regardless of the adjuvant chemotherapeutic regimen or time of recurrence.</div></div><div><h3>Conclusions</h3><div>PRS was similar between patients who received adjuvant chemotherapy with DS or with S-1 alone. PRS was also similar between groups of patients who received chemotherapy after recurrence. Platinum-based chemotherapy might be the optimal treatment for patients who develop recurrence after completing adjuvant DS, regardless of the time of recurrence.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"219 ","pages":"Article 115322"},"PeriodicalIF":7.6,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143480626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}